Curis skyrockets 448% after encouraging phase 1 data for leukemia treatment (CRIS)
NYSE trader

Spencer Platt/Getty Images

  • Small-cap biotechnology firm Curis surged as much as 448% on Tuesday after the company released encouraging phase I data for its leukemia treatment, CA-4948.
  • The company said it observed a Marrow complete response in two patients, as well as a reduction of marrow blasts observed in all evaluable patients in the study.
  • The company expects to report additional phase I data of the study in the second half of 2021.
  • Visit Business Insider’s homepage for more stories.

Curis, Inc. staged an eye-popping rally on Tuesday after it released positive preliminary data related to its phase one trial of CA-4948, a small molecule inhibitor that is being tested in patients with acute myeloid leukemia.

Curis shares jumped as much as 448% in Tuesday trades to $7.90. The stock closed at $1.44 on Monday.

The positive preliminary data from the phase one trial included marrow blast reductions observed in all evaluable patients, as well as two patients experiencing a marrow complete response, according to the company.

Dr. Guillermo Garcia-Manero of The University of Texas MD Anderson Cancer Center said, “These preliminary data suggest, for the first time in a clinical setting, that successfully targeting the long isoform of IRAK4…could be the first major breakthrough in over a decade for patients with these diseases.”

Curis will continue to advance the study of CA-4948 and expects to report additional phase one data in the second half of 2021. 

Read more: Morgan Stanley’s consumer analysts share 13 high-conviction global stocks to buy to capitalize on the continuing economic recovery

cris trial.JPG

Markets Insider

Read More